More than 12 000 children and adolescents are diagnosed with cancer each year in the United States. 1 Advancements in therapeutic and supportive care strategies have resulted in significant improvements in survival; the overall 5-year survival rate is approaching 80%. 1 However, two-thirds of these survivors experience at least one chronic health condition, 2 resulting in considerable morbidity and premature mortality among childhood cancer survivors. 3 A clear and unambiguous relation exists between therapeutic exposures and specific adverse events experienced by the survivors. A brief overview illustrates the therapeutic exposure-adverse event relation observed in childhood cancer survivors. This overview reinforces the need to develop risk-reduction strategies in childhood cancer survivors, as exemplified by the study conducted by Lipshultz et al 4 in this issue of Pediatrics that focuses on use of continuous infusion anthracyclines to reduce the risk of cardiomyopathy.
retain ovarian function after completion of therapy, yet will experience premature menopause before 40 years of age. 13 Older age at treatment, exposure to abdominal or pelvic radiation, and exposure to alkylating agents have been associated with increased risk of ovarian failure. 12, 13 Patients treated with radiation involving the thyroid gland are at risk for developing hypothyroidism. 14 Risk factors include female gender, young age at treatment, and radiation dose.
Severe growth retardation has been observed in as many as 30% to 35% of survivors of childhood brain tumors 15 and in 10% to 15% of patients treated with some antileukemia regimens. 16 Whole-brain irradiation is the single most important risk factor; children younger than 5 years at radiation are particularly susceptible.
Platinum-containing chemotherapy causes serious, permanent, bilateral hearing loss in more than 60% of children receiving the drug. 17 Risk of dosedependent platinum-related hearing loss is modified by exposure to other ototoxic agents and young age at exposure.
In addition to the specific treatmentrelated long-term nonmalignant complications described previously, exposure to radiation and chemotherapy increase the risk of developing histologically distinct new malignancies or second malignant neoplasms (SMNs). The cumulative incidence of SMNs exceeds 20% at 30 years after diagnosis of childhood cancer, representing a four-to sixfold increased risk for cancer survivors, compared with the general population. 18 SMNs are classified into 2 distinct groups: chemotherapyrelated myelodysplasia and acute myeloid leukemia, and radiation-related solid SMNs. Chemotherapy-related myelodysplasia and acute myeloid leukemia is classically associated with exposure to alkylating agents and topoisomerase II inhibitors. Radiation induces solid SMNs within the radiation field. The risk is highest when radiation exposure occurs at a younger age, and increases with increasing doses of radiation and with increasing time since radiation. Some of the well-established radiation-related solid SMNs include breast cancer, 19 thyroid cancer, 20 brain tumors, 21 and sarcomas. 22 As shown here, the health and wellbeing of childhood cancer survivors have been studied quite thoroughly for the first 2 to 3 decades after diagnosis of the primary cancer. Specifically, the burden of morbidity has been described in terms of the magnitude of risk, the relationship with specific therapeutic exposures, and subgroups at particularly high risk have been identified. This research has informed the development of the Children' s Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers 23 (guidelines can be downloaded from www.survivorshipguidelines.org). This research has also informed primary prevention strategies that have resulted in a reduction in dose or elimination of use of certain therapeutic agents. Research is currently focused on understanding the pathogenesis of these adverse outcomes, and on developing intervention strategies.
It is important to note that more than ∼19% of all children in the United States live with a chronic health condition resulting in a special health care need. 24 Examples of chronic health conditions include asthma, diabetes, cerebral palsy, sickle cell anemia, cystic fibrosis, AIDS, epilepsy, spina bifida, congenital heart problems, and, of course, cancer. Management of these conditions involves exposure to a variety of therapeutic agents on a chronic basis, with a potential for long-term organ toxicities, with significant impact on the morbidity and mortality in these populations. Using the childhood cancer outcomes research paradigm in patients with other chronic health conditions would help describe the landscape of long-term treatmentrelated toxicity and identify vulnerable subpopulations with the ultimate goal to reduce long-term morbidity and mortality.
